李良成博士、副教授
个人简历：
2001年毕业于中国医学科学院、中国协和医科大学药物研究所，获理学博士学位。2002年起先后在美国新泽西医科和牙科大学，美国伊利诺伊大学芝加哥分校从事博士后及访问学者研究，现为厦门大学药学院副教授。长期以来从事肿瘤、自身免疫性疾病和糖尿病的发病机理及药物开发研究。已申请一项专利（Pub. NO. US 20110117627 A1),并有多篇文章在Cancer Research，Diabetes, The Journal of Biological Chemistry，J. Immunology，PlosOne, Thyroid, Acta Pharmaceutica Sinica 等专业杂志上发表，目前是Plos One, Toxicology and Applied Pharmacology等多家专业杂志的审稿人。研究成果曾获第七届全国生化药理学研讨会优秀青年论文一等奖。
教育背景：
1998-2001中国医学科学院、中国协和医科大学药物研究所,药理学获理学博士学位
1993-1996中国科学院西北高原生物研究所,神经生物学获理学硕士学位
1987-1991中国农业大学生物学院,动物生理与生物化学获理学学士学位
主要研究方向：
1.从事生化和分子药理学研究；
2.研究囊泡转运在疾病，如肿瘤、自身免疫性疾病和糖尿病发生中的作用；
3.研究基因的选择性剪切在上述疾病发生过程中的作用及机理；
4.建立治疗肿瘤、自身免疫性疾病及糖尿病的药物筛选模型及新药开发。
代表性论文：
1.侯琦李良成郭颖程桂芳. 异丹叶大黄素对人滑膜细胞白细胞介素-8生成及mRNA的影响药学学报2001,36:407-410.
2. Li, L-C., Shen, F., Hou, Q., and Cheng, GF. Inhibitory effect of meloxicam on human polymorphonuclear leukocyte adhesion to human synovial cell. Acta Pharmaceutica Sinica, 2002, 37:103-107. (SCI impact factor: 1.162)
3. Li, L-C., Hou,Q., Guo, Y., and Cheng, GF. Inhibitory effect and mechanism of action of Saggenon C on human polymorphonuclear leukocyte adhesion to human synovial cell. Acta Pharmacol Sin. 2002, 23(2):138-142.(SCI impact factor: 1.677)
4. Sheng, JR, Li, L-C and Meriggioli, MN et al. Suppression of Experimental Autoimmune Myasthenia Gravis by Granulocyte-Macrophage Colony-Stimulating Factor Is Associated with an Expansion of FoxP3+ Regulatory T Cells. J. Immuno. 2006 , 177(8):5296-306. (SCI impact factor: 5.520)
5. Meriggioli, MN, Sheng, JR, Li, L-C, Prabhakar, BS. Strategies for treating autoimmunity: novel insights from experimental myasthenia gravis. Ann N Y Acad Sci. 2008;1132:276-82. (SCI impact factor: 4.364)
6. Sheng, JR., Li, LC, Ganesh, BB, Prabhakar, BS, Meriggioli, MN. Regulatory T cells induced by GM-CSF suppress ongoing experimental myasthenia gravis. Clin Immunol. 2008, 128(2):172-80. (SCI impact factor: 3.648)
7. Li, L-C., Sheng, JR, Mulherkar, N., Prabhakar, BS., Meriggio MN. Regulation of apoptosis and caspase-8 expression in nueroblastoma cells by isoform of the IG20 gene. 2008, Cancer Res. 15;68(18):7352-61. (SCI impact factor: 8.650)
8. Sheng, JR, Li, L-C, Prabhakar BS, Meriggioli, MN. Acetylcholine receptor-alpha subunit expression in myasthenia gravis: a role for the autoantigen in pathogenesis? Muscle Nerve. 2009,40(2):279-86. (SCI impact factor: 2.314)
9. Kurada, BRVVSNK*. Li, L-C*., Subramanian M.,Mulherkar, N.,Prasad KV., Prabhakar, BS.MADD, a splice variant of IG20, is indispensable for MAPK activation and protection against apoptosis upon TNF treatment.J. Bio. Chem. 2009,284 (20):13533-41 (* co-first author) . (SCI impact factor: 4.651)
10. Li, L-C. Jayarama, S., Ganesh, L., Qian, L-X., Rotmensch, J., Prabhakar, BS., Knockdown of MADD and c-FLIP overcome resistance to TRAIL-induced apoptosis in ovarian cancer cells.Am J Obstet Gynecol. 2011, 205(4): 362.e12-25. (SCI impact factor: 3.877)
11. Li, L-C*, Jayarama, S., *, Pilli T., *,Qian, L-X. ,Ganesh, L., Pacini, F., Prabhakar, BS.,Abrogation of the IG20 gene expression renders TRAIL resistant thyroid cancer cells susceptible to TRAIL treatment. Thyroid, 2013, 23(1):70-8.(SCI impact factor: 3.544)
12. Turner, A*., Li, L-C*., Pilli, T., Qian, L-X., Wiley, EL., Prabhakar, BS., MADD knock-down enhances doxorubicin and TRAIL induced apoptosis in breast cancer cells. Plos One 2013, 8(2): e56817. (* co-first author). (SCI impact factor: 4.24)
13. Jayarama, S.*, Li, L-C,*,Ganesh, L.*, Mardi, PK., Hay, N., Li,PF., Prabhakar, BS. MADD is a downstream target of PTEN in triggering apoptosis. J. Cell. Biochem. 2014,115 (2): 261-70 (* co-first author). (SCI impact factor: 4.651)
14. Li, L-C., Wang, Y., Carr, R., Haddad, Li, Z., Qian, L-X.,Oberholzer, J., Maker, AV., Wang, Q., Prabhakar, BS., IG20/MADD Plays a Critical Role in Glucose-Induced Insulin Secretion.Diabetes, 2013, Dec.30. (SCI impact factor: 8.3)
15. Thiruppathi, M, Sheng, JR, Li, L-C, Prabhakar, BS, Meriggioli, MN. Recombinant IgG2a Fc (M045) multimers effectively suppress experimental autoimmune myasthenia gravis. J Autoimmun. 2014 Jan 2. pii: S0896-8411(13)00161-3. (SCI impact factor: 6.075)
联系方式：
地址：福建省厦门市翔安区翔安南路厦门大学药学院
邮编：361102
电话：0592-2881126
E-mail：lchli2013@xmu.edu.cn
